Cargando…

Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center

Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is rapidly increasing, paralleling the aging of the population. cSCC predominantly affects chronically sun-exposed areas, such as the head and neck region. At our tertiary center, a multidisciplinary approach to non-melanoma skin...

Descripción completa

Detalles Bibliográficos
Autores principales: Denaro, Nerina, Passoni, Emanuela, Indini, Alice, Nazzaro, Gianluca, Beltramini, Giada Anna, Benzecry, Valentina, Colombo, Giuseppe, Cauchi, Carolina, Solinas, Cinzia, Scartozzi, Mario, Marzano, Angelo Valerio, Garrone, Ornella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534594/
https://www.ncbi.nlm.nih.gov/pubmed/37766176
http://dx.doi.org/10.3390/vaccines11091500
_version_ 1785112431269249024
author Denaro, Nerina
Passoni, Emanuela
Indini, Alice
Nazzaro, Gianluca
Beltramini, Giada Anna
Benzecry, Valentina
Colombo, Giuseppe
Cauchi, Carolina
Solinas, Cinzia
Scartozzi, Mario
Marzano, Angelo Valerio
Garrone, Ornella
author_facet Denaro, Nerina
Passoni, Emanuela
Indini, Alice
Nazzaro, Gianluca
Beltramini, Giada Anna
Benzecry, Valentina
Colombo, Giuseppe
Cauchi, Carolina
Solinas, Cinzia
Scartozzi, Mario
Marzano, Angelo Valerio
Garrone, Ornella
author_sort Denaro, Nerina
collection PubMed
description Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is rapidly increasing, paralleling the aging of the population. cSCC predominantly affects chronically sun-exposed areas, such as the head and neck region. At our tertiary center, a multidisciplinary approach to non-melanoma skin cancer is provided for locally advanced cSCC. Methods: We retrospectively revised all patients with locally advanced/metastatic cSCC treated with anti-PD1 antibody (Cemiplimab) at our Institution from January 2020 to March 2023 (minimum follow-up of 4 months on treatment). Results: Overall, we consecutively treated 20 ultra-octogenarian patients, of whom 15 were males and 5 were females (median age: 86.9 years). Despite age, a median number of concomitant drugs, and comorbidities, efficacy, and safety were superimposable with the available literature. No patients reported treatment-related adverse events of grade 3 or higher. Grade 2 adverse events were reported in 25% of patients. Overall, the response rate was 65%, with 50% partial responses and 20% long-lasting stable disease. The median duration of response was 14 months. The G8 elderly score was assessed in all patients, and the median score was 12 (range 9–14). Conclusions: Among ultra-octogenarian patients, a clinical benefit from Cemiplimab was obtained in most, including tumor shrinkage and pain relief. Cemiplimab confirmed its effectiveness in elderly patients in a real-life setting, with no new safety concerns.
format Online
Article
Text
id pubmed-10534594
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105345942023-09-29 Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center Denaro, Nerina Passoni, Emanuela Indini, Alice Nazzaro, Gianluca Beltramini, Giada Anna Benzecry, Valentina Colombo, Giuseppe Cauchi, Carolina Solinas, Cinzia Scartozzi, Mario Marzano, Angelo Valerio Garrone, Ornella Vaccines (Basel) Article Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is rapidly increasing, paralleling the aging of the population. cSCC predominantly affects chronically sun-exposed areas, such as the head and neck region. At our tertiary center, a multidisciplinary approach to non-melanoma skin cancer is provided for locally advanced cSCC. Methods: We retrospectively revised all patients with locally advanced/metastatic cSCC treated with anti-PD1 antibody (Cemiplimab) at our Institution from January 2020 to March 2023 (minimum follow-up of 4 months on treatment). Results: Overall, we consecutively treated 20 ultra-octogenarian patients, of whom 15 were males and 5 were females (median age: 86.9 years). Despite age, a median number of concomitant drugs, and comorbidities, efficacy, and safety were superimposable with the available literature. No patients reported treatment-related adverse events of grade 3 or higher. Grade 2 adverse events were reported in 25% of patients. Overall, the response rate was 65%, with 50% partial responses and 20% long-lasting stable disease. The median duration of response was 14 months. The G8 elderly score was assessed in all patients, and the median score was 12 (range 9–14). Conclusions: Among ultra-octogenarian patients, a clinical benefit from Cemiplimab was obtained in most, including tumor shrinkage and pain relief. Cemiplimab confirmed its effectiveness in elderly patients in a real-life setting, with no new safety concerns. MDPI 2023-09-18 /pmc/articles/PMC10534594/ /pubmed/37766176 http://dx.doi.org/10.3390/vaccines11091500 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Denaro, Nerina
Passoni, Emanuela
Indini, Alice
Nazzaro, Gianluca
Beltramini, Giada Anna
Benzecry, Valentina
Colombo, Giuseppe
Cauchi, Carolina
Solinas, Cinzia
Scartozzi, Mario
Marzano, Angelo Valerio
Garrone, Ornella
Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
title Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
title_full Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
title_fullStr Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
title_full_unstemmed Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
title_short Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
title_sort cemiplimab in ultra-octogenarian patients with cutaneous squamous cell carcinoma: the real-life experience of a tertiary referral center
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534594/
https://www.ncbi.nlm.nih.gov/pubmed/37766176
http://dx.doi.org/10.3390/vaccines11091500
work_keys_str_mv AT denaronerina cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT passoniemanuela cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT indinialice cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT nazzarogianluca cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT beltraminigiadaanna cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT benzecryvalentina cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT colombogiuseppe cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT cauchicarolina cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT solinascinzia cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT scartozzimario cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT marzanoangelovalerio cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter
AT garroneornella cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter